Conviction: Medium
Status: Holding (claude-trader paper position)
Quick Snapshot
| Signal |
Reading |
| Overall |
🟢 STILL EXTREME OVERSOLD - RSI 9, surgical robotics monopoly at deep discount |
| Moat |
Wide |
| Key insight |
RSI 8-9 for 14+ consecutive days. Historically extreme. da Vinci 5 FDA cardiac expansion bullish. |
Action Matrix
| Action |
Level |
Why |
| Current |
✅ Buy/Hold |
RSI 9 = extreme oversold, wide moat monopoly |
| Entry Zone |
$460 - $500 |
Current price deep in zone |
| Stop-Loss |
$404.87 (-15%) |
Below 52-week low support |
| Target |
$600 (+26%) |
Return to 30D ago levels |
Price Data
| Metric |
Value |
Change from 02/05 |
| Current Price |
$476.32 |
Flat ($0 change) |
| RSI |
8.8 |
Was 9 (still extreme) |
| SMA20 |
$527.40 |
Price 9.7% below SMA |
| 30D Change |
-19.7% |
Holding at lows |
| 52-Week High |
$609.08 |
-21.8% from highs |
Update from 02/05: Price stabilized at $476.32 (unchanged from 02/05). RSI still at extreme 8.8. 14+ consecutive days below RSI 11. This is historically unprecedented for a quality monopoly.
Company Overview
| Question |
Answer |
| What they sell |
da Vinci surgical robots, Ion endoluminal system, instruments, services |
| Who pays |
Hospitals, surgical centers worldwide |
| Revenue model |
Capital sales + recurring instruments/accessories + service contracts |
| Market share |
~80% global surgical robotics |
| Moat |
Wide (9,000+ installed systems, 4,600+ patents, surgeon training ecosystem) |
Key Segments
| Segment |
Revenue % |
Growth |
Notes |
| Instruments & Accessories |
~57% |
+15-18% |
Recurring per-procedure revenue |
| Systems |
~27% |
Variable |
Capital equipment sales |
| Services |
~16% |
+10-12% |
Maintenance, training |
Financials & Leading Indicators
| Indicator |
Value |
Signal |
| Revenue Growth YoY |
~17% |
🟢 Accelerating |
| Gross Margin |
~67% |
🟢 Expanding |
| Operating Margin |
~30% |
🟢 Strong |
| Earnings Beat Rate |
>80% |
🟢 Consistent |
| Insider Trading |
-$313.9M net |
🔴 Heavy selling |
| Recurring Revenue |
~73% |
🟢 Predictable |
Valuation
| Metric |
Current |
5Y Avg |
Assessment |
| P/E |
~55x |
~65x |
Below average |
| P/S |
~20x |
~25x |
At low end of range |
| P/FCF |
~60x |
~70x |
Improved |
Fair Value: $550 (based on historical avg + DCF). 15.5% upside from current.
Bull Case
| Factor |
Evidence |
| RSI 9 for 14+ days |
Historically extreme - mean reversion likely |
| da Vinci 5 cardiac FDA |
TAM expansion into $10B+ market |
| 80% market share monopoly |
9,000+ systems, 4,600+ patents |
| 73% recurring revenue |
Predictable cash flow from installed base |
Bear Case
| Factor |
Evidence |
| -$313.9M insider selling |
Smart money exiting |
| Still rich valuation |
20x P/S even after drop |
| Competition (Medtronic Hugo) |
2-3 years away but real |
| Healthcare spending risk |
Hospital capex delays possible |
Paper Trade Activity
| Strategy |
Action |
Entry |
Shares |
Value |
P&L |
| claude-trader |
HOLD |
$476.32 |
4 |
$1,905 |
$0 (flat) |
Research Log
| Date |
Update |
| 2026-02-05 |
Created deep dive. RSI 9, extreme oversold. -$313.9M insider selling. |
| 2026-02-09 |
Refreshed. Price flat at $476.32. RSI still 8.8 (14+ days extreme). No catalyst yet but stabilizing. |
The Gold
| Discovery |
Implication |
| RSI 9 for 14+ consecutive days |
Historically extreme for quality monopolies |
| da Vinci 5 cardiac FDA clearance |
TAM expansion catalyst |
| Price stabilized (flat 02/05 to 02/09) |
Possible bottoming formation |
| -$313.9M insider selling |
Caution - may know something |
Open Questions
- Why are insiders selling so aggressively?
- When does da Vinci 5 cardiac volume ramp materially?
- Is RSI 9 driven by sector rotation or ISRG-specific?
- Q4 2025 earnings estimate and procedure volume guidance?
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.